Study: Increased Serum cAMP Levels Observed in Patients With Asthma
Higher levels of cyclic adenosine monophosphate (cAMP) may be key to diagnosing asthma and its severity as well as monitoring patients.
Published: 10/13/2025
News
FDA Approves Cemiplimab as Adjuvant Treatment for Cutaneous Squamous Cell Carcinoma
Cemiplimab's approval is supported by findings from the C-POST clinical trial.
Published: 10/8/2025
Icotrokinra Outperforms Deucravacitinib in Head-to-Head Psoriasis Study
Johnson & Johnson presented new long-term data of icotrokinra from ICONIC-LEAD, along with data from ICONIC-ADVANCE indicating head-to-head superiority with standard-of-care deucravacitinib.
Published: 10/6/2025
Albuterol–Budesonide Combo Boosts Lung Function in Asthma
Research highlights the effectiveness of the albuterol-budesonide combination for ensuring rapid relief and safety in patients with asthma.
Published: 10/6/2025
FDA Approves Roflumilast Cream for Pediatric Patients With Atopic Dermatitis
The approval is supported by findings from the INTEGUMENT-PED trial and the INTEGUMENT-OLE long-term extension study.
Published: 10/6/2025
Stelara Biosimilar SYSA1902 Shows Clinical Equivalence for Plaque Psoriasis
A phase 3 study shows SYSA1902, a biosimilar to Stelara, is clinically equivalent for treating moderate to severe plaque psoriasis.
Published: 10/3/2025
Albuterol/Budesonide Label Updated to Include Clinically Meaningful Evidence From BATURA Study
BATURA demonstrated that albuterol/budesonide significantly reduced severe exacerbation risk reduction in patients with mild asthma.
Published: 10/1/2025
FDA Approves First Oral Targeted BTKi Treatment for Patients With Chronic Hives
Remibrutinib gains FDA approval as the first oral treatment for chronic hives, offering hope for patients unresponsive to standard therapies.
Published: 10/1/2025
FDA Approves Guselkumab for Pediatric Plaque Psoriasis, Psoriatic Arthritis
The FDA approves guselkumab, the first IL-23 inhibitor for pediatric psoriasis and psoriatic arthritis, enhancing treatment options for children.
Published: 9/29/2025
FDA Approves 1.5% Ruxolitinib Cream for Pediatric Atopic Dermatitis
With this approval, an effective, nonsteroidal treatment option is available for young patients.
Published: 9/19/2025
Amlitelimab Meaningfully Clears Skin in Moderate-to-Severe Atopic Dermatitis
Investigators from the phase 3 COAST 1 trial demonstrated the efficacy and safety of amlitelimab in patients with moderate-to-severe atopic dermatitis.
Published: 9/12/2025
COVID-19 Vaccination Could Lower Risk of Developing Asthma
COVID-19 vaccination significantly reduces the risk of asthma and other airway inflammatory diseases, offering vital protection against respiratory complications.
Published: 8/28/2025
Switching From Reference Adalimumab to Biosimilar Shows No Major Differences in Patients With RA, PsA
Biosimilars can be a more affordable and accessible treatment option for patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA).
Published: 8/28/2025
The Farm Effect: What Amish Communities Can Teach Us About Allergy Prevention
The "farm effect" is a term researchers use to describe the protective impact of growing up on traditional farms—especially around livestock, barns, and raw farm environments—on the development of allergies and asthma.
Published: 8/22/2025
Study Reveals Why Some Children Still Have Asthma Attacks Even With Treatment
New research uncovers complex inflammatory pathways driving asthma flare-ups in children, highlighting the need for personalized treatment strategies.
Published: 8/21/2025
Tildrakizumab Improves Signs, Symptoms of Active Psoriatic Arthritis in Phase 3 Studies
Tildrakizumab 100 mg shows significant efficacy in treating psoriatic arthritis, achieving key clinical trial end points and offering hope for patients.
Published: 7/29/2025
Delgocitinib Cream Becomes First, Only Approved Treatment for Moderate-to-Severe Chronic Hand Eczema
The approval represents a major advancement for patients with moderate-to-severe chronic hand eczema, as delgocitinib becomes the first treatment available for this population in the US.
Published: 7/24/2025
FDA Issues CRL to Replimune for Vusolimogene Oderparepvec With Nivolumab for Advanced Melanoma
The complete response letter (CRL) did not raise safety concerns, but stated the IGNYTE trial was inadequate and did not provide substantial evidence of effectiveness.
Published: 7/22/2025
Showing 1 to 19 of 218 articles